Copenhagen, Denmark, June 26, 2014 / B3C newswire / - Nuevolution is very pleased to announce that Dr. Peter Hirth has joined Nuevolution as a Corporate Advisor. Peter brings 30 years of experience in biotechnology and pharmaceutical discovery to Nuevolution, explicitly from his tremendous successes with companies like SUGEN and Plexxikon.
At SUGEN, Peter grew the company from its inception, and he led the company in its successful clinical development of several kinase inhibitors within oncology. SUGEN was acquired by Pharmacia in 1999 and Peter served as President until 2000.
Platform based biotech Plexxikon, which was co-founded by Peter in 2000, gained its successes through the pioneering work within fragment based drug discovery, which resulted in the development of several NCEs in a variety of indications. Most know in Plexxikon’s portfolio was the successful development and launch of Zelboraf™ for the treatment of patients with BRAFV600E mutation-positive inoperable or metastatic melanoma. Plexxikon was acquired by Daiichi Sankyo in 2011.
Furthermore and prior to SUGEN, Peter was Vice President at Boehringer Mannheim, and before that, he was a research scientist at the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego.
Peter received his Ph.D. in molecular genetics from Heidelberg University, Germany.
“We are excited about having Peter join us as a Corporate Advisor”, said Alex Gouliaev, CEO of Nuevolution A/S. “Peter brings to Nuevolution a wealth of entrepreneurial experience and life science expertise. I am convinced that his expertise will strongly support our strategic direction of becoming a leading small molecule development company in the field of oncology and inflammation”.
“I am very impressed how the Nuevolution technology has delivered very interesting compounds, especially for typically very difficult targets and I therefore think it will provide for drug candidates in areas where others have great difficulties and thus offers a very important and differentiated approach to drug discovery”, Peter Hirth commented.
Nuevolution’s powerful lead discovery platform is currently being applied against a vast number of therapeutically important targets within oncology and inflammation and several programs are currently progressing though discovery, PK-optimization in vivo POC studies.
In parallel with delivering novel small molecule compounds alone as well as in collaboration with pharmaceutical companies, Nuevolution will continue to form partnerships around its drug discovery platform technology.
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology, which represents the ultimate fragment, based drug discovery technology. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented speed and scale.
Nuevolution partners its technology with pharmaceutical and biotechnology companies, and has entered into drug discovery agreements with Merck, Novartis, Boehringer Ingelheim, Cancer Research Technology and The Institute of Cancer Research. Furthermore, Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered technology licensing agreements with Nuevolution. Nuevolution participates in a scientific joint venture consortium (Nuevolution, Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals) focusing on GPCR’s, and Nuevolution is currently in the optimization phase for compounds identified under a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and BRIC focusing on epigenetics. Nuevolution has demonstrated the power of Chemetics® by identification of highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation and oncology. Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital, Industrifonden, SLS Invest, Novo Ventures and Innoventus Life Sciences.
Chemetics® is a registered trademark of Nuevolution.
Chemetics® is a patented technology of Nuevolution: EP1402024, US7,727,713, EP1487978, US7,413,854, EP1756277, EP1608748, US 7,915,201, EP1558744, AU2003273792, CN-ZL20038010476, HKHK1082742, IN213390, IL167531, JP4895608, ZA2005/02624, NZ538993, SG111515, US8,206,901, US7,704,925, EP1957644,EP07114663.3, EP10184311.8, US12/330,709, EP08169346.7, US12/179,323, EP03766117.0, US10/523,006, US10/539,288, US13/179,283, EP09154197.9, AU2011226815, CA2,544,153, CN201210222023.8, EP10183942.1, EP10184069.2, HK11107861.8, HK11107866.3, IL207672, IL207673, IN178/MUMNP/2007, JP2010-226107, JP2013-155967, US11/402,957, US13/455,223, US10/572,644, EP10192716.8, EP10192717.6, US12/095,778, EP09765460.2, US12/999,267, EP11720372.9, IN9924/DELNP/2012, US13/641,588.
For further information about Nuevolution A/S, please visit the company’s website www.nuevolution.com.
For further enquiries about Nuevolution please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 7020 0987